Decoding the DNA Opportunity with Anne Wojcicki (23andMe)

Anne Wojcicki
1 follower
2 Video Views·Dec 31, 2025
Anne Wojcicki co-founded 23andMe to empower consumers with their genetic information. Now, 12 years after its founding, hear from CEO Wojcicki on the tremendous opportunities that can be unlocked by genetic testing.
Hey, hi, so your company 23andMe, it's a catchy name, uses spit tube
tests to test from anything from where our genetic ancestry came from, to health traits, to whether or not we are
going to be
more prone to drinking coffee.
But in the last few years you've also gotten into a lot of research projects, and I want to know
what do our genetic data have to do with Pantene and Pepto-Bismol?
Oh, do we, is there something? Isn't there something? With Pantene and Pepto-Bismol? Yeah, with P&G Beauty?
You know, we have, we've done a number of research partnerships, like we look at
you know, the beauty of what we have done, like when I was on Wall Street, I always felt like, you know, people have
you know, a Crohn's study, and
they find all these people with Crohn's disease, and they only study Crohn's, and then they have a heart disease study,
and they only study heart disease, and I kept thinking, like, people are not
mono-disease, like they, they have, like, the people with Crohn's also,
some of them like Pantene, some of them have allergies when they dye their hair, some of them also have heart issues, like people have
everything, and
you know, the beauty of what we've tried to create is this, is this community of people where
people tell us all kinds of things about themselves, and then you have the ability to participate in all kinds of research.
So, you, my, like, we have a family history of, you know, breast cancer, and my, my former husband,
he has a family history of Parkinson's. We could be a control for you if you said, oh, you had,
you know, Crohn's in your family, you could be, you know, you have Crohn's, like, we can be controls for each other, and that we can
answer questions about
everything. So, it's been really fun for us to do research in a number of the traditional disease areas,
but also ask people about their daily life, like, what is it that is
interesting? Like, all of us use shampoo, you know, some more than others,
and, you know, makeup, etc., like, but
wellness and lifestyle is a really interesting area for us to do research, and in some ways those areas, you know, NIH does not
frequently fund
wellness studies and, and sort of that, that, that personal care kind of area,
and so it's a way that we can leverage the database that we've in the community to people that we have
into all kinds of very different research topics that are not generally funded.
I think one of the really interesting research topics lately is into cannabis. Yeah, oh, I agree with that. So, cannabis,
you know, we've, we've participated in some research projects on that,
but I think it's a whole, especially in this, we're kind of in this hybrid state of legalization, and a lot of people self-medicate.
So, but because it's not federally legal,
it's a, you can't get federal dollars to study, well, what really is the interaction between cannabis and antidepressants, and,
you know, in pregnancy, and people use it a lot to self-medicate in, you know, again, in cancer and depression, and obviously clearly with
recreational,
but there's not a lot of data about that. And so I think that's another area I, again, because it's, I feel like 23andMe,
we represent research that's interesting to the people,
that we have an opportunity to actually do research projects on, again, on things like shampoo and cannabis.
Yeah, thank you. And, and I think,
along with, not only research, but also using our DNA data for good. You, you recently, you saw the crisis at the border.
There are still hundreds of families that are still separated, and you,
you offered to do something about it. What was that? We did. We offered,
we offered to give away kits to families that have been separated, and,
you know, a core part of our business is reuniting families. So we have ways,
we said we are willing to create a custom product, essentially, for these families. So you're just matching
within that group, and not necessarily as broadly. They wouldn't be part of the normal experience.
It didn't move forward because of all kinds of
political questions and privacy questions, and so it just, my goal, like, that was such a complicated situation.
My goal was to try and help, but I didn't want to add to the chaos of, like, our agenda.
Yeah. So, so we, we offered to help, and I think 23andMe, we donate kits all the time.
We think about, again, diversity. We think about ways that we can help families.
So, like, we try to be a company very much with a corporate soul,
and that was an area where we said we're happy to help if it's helpful,
but we also are not going to push ourselves if it's not helpful.
Sure, yeah, and from what I understand, the nonprofits didn't take you up on it because of the privacy concerns.
Yeah, and that was workable. I think it was one of those things, again, we were willing, we said we could set up a
separate community for them,
but it wasn't something that they wanted to pursue, which is fine.
Is it something that you can pursue internally? Is there something that you can add time and resources to internally?
We can't find, I can't, the main question is you have to get access to the people, and so, like, without them,
I can't do much. Right, you don't have a list of who's who.
I don't have a list of who's who, and apparently the government doesn't have a list of who's who.
I, I think that we, we would actually need their saliva, like, we can't, there's, there's a limit to what we can do without the
actual physical person there, if that makes sense.
I want to talk about drugs with you, not just cannabis, but also you recently pulled in
$300 million from GlaxoSmithKline, and what I want to know is, what are you hoping to come from that partnership?
I, I love, I love this, the GSK partnership, so,
since, so from my Wall Street days, like, one of the things that I found remarkable is how
horribly inefficient drug development is. So, I used to joke, because I lived in Poland briefly,
I was like, it reminded me of communist times, like, it was the only industry I knew
that actively bragged about how they got worse every year. Like, so, when I started investing in 1996,
it was $700 million to make a drug, and when I left, it was $3 billion to make a drug.
Like, who does that outside of communism? So, I, I was like, a passion for me is, like,
you know, what is a way that you could actually make drug development more efficient? And ultimately, you know, people have all kinds of mixed feelings about
drug development companies, and, but ultimately, like, if you're somebody who has hepatitis C,
you are very grateful to Gilead for making that drug come to market that cures hepatitis C. So,
ultimately, like, I want us to be in the business of actually
having a meaningful impact on our customers' lives, and if some of our customers want to prevent disease,
we're going to help them prevent disease, but for those customers who actually have a disease,
we want to be, see, can we be part of the solution of curing that disease?
And so, that's the reason to say we're bringing in together all of these people, and if we start with human genetics,
is it possible that we are going to have a higher success rate than the rest of the industry?
So, when you look at the $3 billion it takes to develop a drug, a lot of the reason it's so expensive is because almost
everything fails, and
so we're looking to see if we start with human genetics, do we have a higher likelihood of success?
And I think there's potentially no better
feeling for our customers of saying, you guys have been part of a cure for, or a successful treatment for
depression, or Crohn's, or Parkinson's disease. So, we're really trying to see,
you know, again, have this huge community, have people who are consented and engaged in that research, and develop, you know, those
therapies. What happened, the reason why we signed up with GSK,
is that, I joke, like each one of our molecules is like a child.
So, you know, we have over 10 children in development, and it becomes at some point a lot, like it is,
it is a lot to scale that, and
GSK, what they do, they have a phenomenal team, they understand genetics, and they know how to scale.
It's like thousands of people in the building, who really, like they spend their entire lives
dedicated to trying to develop drugs, and make an improvement in people's lives.
So, it's a great partnership, because we have this engine that can develop ideas,
and we need a partner who can help us really scale. And I have incredible faith in the CEO, Emma, the head of research,
Hal, Aaron, like it's a phenomenal team of people, and again, I think for me,
because we're such a mission-driven company,
finding a company as well that has a soul, and is willing, like we're, you know,
it's not everyone wants to partner with us, like we have a radical mission of like, we will always do what's in the best interest of
our customer. And so,
GSK is the type of company that is really willing to think about, how do we actually treat people differently in a clinical trial?
How do we make sure that people feel engaged?
Like, what is the right way that we can do this, that really gives back to our customers. At the same time,
and you have, what, potential three million people to add to their data set. At the same time,
there have to be some privacy concerns, right?
So, how do you handle, people have opted into 23andMe, and they've opted into 23andMe research,
but how do you handle privacy and data going to GlaxoSmithKline?
So, two things. First, the data doesn't go to GlaxoSmithKline, like it stays,
it's, your data is consented to stay within 23andMe. So, we're working with them on
analysis, but the data is staying within 23andMe. Secondly, one of the first things we did when we signed, when we have this announcement,
we emailed our customers to say, if you do not want to participate, and you want to change your consent status,
here is how you do it. So,
23andMe, for me, is like, all about our customers having agency. If you want to,
like, participate in research, that's awesome, participate in research. If you do not want to participate in research,
that's also awesome, like, you don't have to. And if you want to share your data
with your friends and family and others, share it. If you don't want to, don't. So, we've tried to make it, like,
again, the way so many other aspects of your life work, like, like you're an adult.
If you want to share, share. If you want to participate, participate. We try to make it really clear for people
what's happening, and if you do not want to participate in research, you can just opt out.
So, they, they're already automatically opted in. They have to go and opt out?
Well, if you, for instance, are a customer, and you have opted in to research,
we send you a message saying, we are doing this research program, and we ask you, do you want to, I mean,
we're not asking whether or not you want to say yes again,
but you have that opportunity at that moment then, or you have the opportunity at any time to say you do not want to participate then.
Okay, so if you have opted in, then it goes, and I understand it's anonymized data that goes to Glaxo. It's always anonymized.
It's not, there's no data going to Glaxo.
So, to me, that's like one of the most important things. Like, the data is not going over there.
It's staying within? It stays within 23andMe, and what we do is imagine, like, we're looking at all this analysis on,
let's say, Chrome, and we look at, you know, 20,000 people, and we say, okay, look,
there's this mutation here, and there's a mutation here, and those look like potential drug targets.
You know, no one wants the individual level data. It's not interesting.
Like, what you want is the conclusion from the aggregate information
to say, and what Glaxo is great at is that follow-up, like, the follow-up of, like, how is it, like, again, for our,
what I refer to as our children, our drugs in development or in research, is that
all of those require a lot of wet lab work, and that's where GSK can scale.
Like, they have all kinds of ways to be able to scale that development process.
So you are doing the research internally and then telling them, based on our research, this is what we see.
We collaborate. We work with them on that. We'll go through, and we'll say, hey,
here's what we're finding on the aggregate data. Got it. And say, and then we, again, we look at it,
we've always said that there's a funnel.
You know, there's, like, all kinds of interesting ideas that come at the top.
We kind of sift it through the funnel, and then we go through with them what is it that comes out.
And that's how you present something. You present something like Cambridge Analytica, where a third party has it, and then
someone else can access it.
Yeah, we've always been pretty clear about, I mean, I think one of the big issues that come in, and I'm not an expert in Cambridge Analytica,
but, like, we've always been really clear, it should be your choice about how your information is used.
Like, I had this incident that really bothered me, where I had this procedure at Stanford,
and then suddenly I got an email from Kaiser that said, we will not pay for your procedure.
And I was really offended. I was like, I never asked you to pay.
Like, how did you know?
Like, it really bothers me.
Like, these things, like, why?
Like, you have no idea where your health information is.
Like, at a minimum, like, what 23andMe is trying to do is at least say, like, you're in charge.
You're in power.
Like, if you, like, all of us, like, when we have a friend and family who is sick, it's a painful experience,
because, like, we really don't treat many diseases well.
So we're trying to move the needle in that way.
If you want to participate, it's totally great.
If you don't want to participate, you absolutely don't have to.
So we will always keep iterating in terms of what are ways that we can improve privacy.
We get feedback from people.
But we really, since day one, we have thought an excessive amount about, like,
what are ways that we can make sure that you are empowered, that we're transparent,
and that we're doing what we can on your privacy.
You also told the Wall Street Journal the existing health care system is focused on treatment,
not prevention, because prevention doesn't make money.
Sure.
So you're working with these drug companies, which, by and large, make drugs for treatment.
I want to know, what is 23andMe doing for prevention?
We do, I would say the majority, like, our product today is really focused on prevention.
So you sign up for 23andMe, and we tell you what are some of your risk factors.
So, for instance, you're high risk for macular degeneration, and you're 20 years old.
And macular degeneration is the leading cause of going blind.
So there's things.
There's potentially vitamins.
There's wearing sunglasses.
There's a lot of steps you can potentially take.
If at 50, when you turn 50, you should go and get an eye exam to see whether or not
you actually have the beginnings of macular degeneration.
There are, in this case, drugs to treat it if you do have it.
But preventing losing your eyesight is, like, one of the most important things you can do
to maintain your, like, independence as an adult.
And so I think about, for us, like, all kinds of diseases, with Parkinson's, Alzheimer's,
you know, the whole carrier status area, like we tell you if you had a baby, most people
don't get carrier status testing until they're actually already pregnant, so things like
cystic fibrosis.
Like, we allow people, this is part of what we try to say, is it's so much better to find
out you're a carrier for cystic fibrosis before you're pregnant, because once you're pregnant,
it's more challenging.
There's more ethical questions to think about.
So we really think about what are ways we can get you this information sooner.
We did do, last year, we launched the, or actually, this year, I think, I can't remember,
this year's our scoring, we launched the largest weight loss study, so 70,000 people looking
at a six-arm study, looking at different ways, are there genetics in weight loss?
So I would say, in some ways, we're a 12-year-old company, we're not profitable, the majority
of our work, like, I'm constantly reminded, like, we are, we have to have the balance
of, like, we are, we do want, we want to develop cures and treatments, we also really
want to do what's right for the consumer, and we think a lot about prevention.
And I think that that's where you will see us focusing more and more, a number of the
reports rolling out, we're specifically thinking about ways that we can help consumers prevent
disease.
Is that, weight loss study, is that where you tell us if we have the vaccine or not?
We have.
Is that different?
We don't, so what we do is we have a weight report, whether or not you're genetically
likely to weigh more or weigh less, and so no, we targeted, that is just, it's one of
our, it's one of our, what's one of our wellness reports that we have out there.
So we do think a lot, like, wellness and prevention, and just going on, because this is such a
hot topic for me, you know, Alzheimer's is a real issue, and I can look at my data set
and say we have 20% of our customers who are genetically higher risk for Alzheimer's, and
Alzheimer's prevention study, like, when I ask academics and pharma companies about it,
they're like, you know, you can never do a prevention study.
It's like, it's so expensive, it's impossible to control for, but I think these are ways,
like, 23andMe is uniquely set up to really do that kind of longitudinal prevention study.
So we are talking about specifically in Parkinson's, because I also have people who are genetically
high risk for Parkinson's, can we actually do an interventional study, you know, that's
going to be a, you know, a 10-year study, thinking about are there behaviors that specifically
help prevent or mitigate the outcome of the disease.
So I think in Alzheimer's, there's all kinds of things that we can do, and this is a big
priority for me, and I think it's, again, one of the things that we're really uniquely
set up to do, and if we don't do it, I don't see anyone else doing it.
You're talking about a lot of these diseases that happen when we're older, and those tend
to be ignored diseases by and large.
I think I read something about Alzheimer's, they're not even trying to work on drugs right
now for Alzheimer's disease.
Are you, what are you doing within 23andMe to look at it?
I mean, besides Alzheimer's, it's really hard.
So there's a number of companies, like we have participated in helping recruit for clinical
studies, there have been some research projects that we've done that are really interesting.
So for instance, the genetic variant that's high risk for Alzheimer's is called APOE.
So we did a project looking at people who were over 80 years old, have one or two copies
of that genetic variant, and they have no cognitive issues.
So they like mentally, we do phone screens, we do online tests.
So those people we call as escapers, they have a genetic variant for it.
They're 80 years old, but they're totally fine.
So those people are really interesting to study because they potentially hold a genetic
clue about why they do not have the disease.
And so that's specifically some of the things that we can do.
We're not pursuing neuroscience and neurodisease right now, but that's specifically projects
that we will do with academics and with pharma partners because we would like to help advance
that area, but we're not the ones leading it right now.
So prevention, it would be really interesting to look at prevention.
But again, that is a really long-term study.
You have such a huge dataset from consumers who have been very active at building it up
and helping with research.
And I'm wondering, because CRISPR is such a hot topic right now, are you doing any
within CRISPR?
Do you plan to do anything there?
We're not doing anything in CRISPR right now.
I think it's, you know, CRISPR is a really interesting tool, but figuring out exactly
how it can be used and how it can be delivered to all the cells in your body.
And it's, you know, my drug development team is, you know, is very practical and realistic.
Like there's a number of projects that they're really excited about that have come from the
But I don't think we're not pursuing it right now.
Okay.
I want to talk about the something else that happened in the news earlier this year, the
Golden State Killer.
Yeah.
And I know you guys didn't, it wasn't your dataset that they used to catch the serial
killer, but there's a very big possibility that law enforcement, and I've heard has come
to you before in the past and said, we need your DNA research.
How do you handle that when law enforcement says we need to catch a serial killer, we
need to catch this person, we need your DNA?
We say no.
So it's one of these, we have a transparency report on the site.
It was, it's really like the Golden State Killer is such an interesting story.
And in some ways, like, I'm really proud of my team because we spent so long thinking
about our consent form and the way we were setting up in those early days.
And that's really, again, we thought through a lot of this.
So this is specifically one of the things that we thought through.
So 23andMe does two things.
One, we require a lot of saliva from our customers, specifically for privacy reasons.
Like, we don't necessarily need that much saliva, but you can't accidentally drool that
much saliva.
You can't accidentally, like, fall asleep somewhere and swab it and stick it in and
like, and send it in and have it work.
So we intentionally thought through to make sure that, like, when you spit, it's your
spit.
The second thing is that we don't allow people to upload data from a different source and
see the DNA families, like the DNA relative finder.
So we don't allow people to do that.
So for instance, in the Golden State Killer example, where they found a sample and they
uploaded it to the data set, and they were able to see, are there any family matches?
We don't allow that for our customers.
So we've, we've set up the, the, we've set up how we structure the product and how we
set up even the initial spitting in a lot of ways to make sure that it's like really
you that is spat intentionally, and that there's not going to be outside data sources that
are put in there to see whether or not they are matching.
Does that ever weigh on you that you have the potential to help catch someone really
bad?
I think that it is, it's not our business.
We're really focused on the empowerment of the consumer and wealth, your health area,
your ancestry, identity, all of those things.
GEDmatch, and there's other groups out there now that say they want to do that specifically
as a business.
That is not something that we are going to be pursuing.
In fact, he cut off API access recently.
The API actually is, is a totally separate issue.
And that one is, it was a little, so again, and we're, we're coming out with a blog post
that we'll put out about it.
So we put out the API with really with this hope that like, oh, there's going to be all
these companies that come and like the world of genetics, everything's going to be personalized.
And kind of what we realized after years is that there's not a lot of people who understand
genetics.
And a lot of the big companies, like people don't yet understand exactly how we are going
to personalize.
And the quality, there's a number of the partners we had that are really interesting,
but they don't meet our scientific bar.
And like what wine you should drink.
Wine, there's a lot of wellness, nutrition that is just like, I'm really, I'm uncomfortable
with it.
And a lot of the reason why we were okay with it is after the FDA, we couldn't return
interpretation to people.
So we felt like it was a better compromise to say, we're going to let you have access
to all this other information, even though we know that there's some errors in it, but
you're kind of, it's, you know, there's a level of independence that you have.
You can go and actually get this different interpretation.
But after BRCA came out, in some ways, the scale tipped because we're giving you a lot
of the really valuable information.
And then a lot of the information that people are getting from other, some of these other
sources was causing a lot of concern, like medical concern.
And then I think that, you know, one of the things I've often said is that healthcare
was the original fake news.
And there's a lot of, like, it's easy to prey on people about a diet or a wellness.
And, and there was some of the information and some of the, you know, companies that
had just a real lack of science that I was uncomfortable with.
So it's not that we shut it off.
It's that we're actually, I'd say we're kind of doing a clean sweep.
And we still do a lot of partnerships with academics.
We do a lot of partnerships around research.
So those all use the API.
And we will keep doing partnerships with companies that meet our scientific criteria.
But I think that customers, I feel really strongly about this, like, it's really hard
for people to necessarily know exactly what is real and what is fake.
And we have a responsibility to make sure that we're providing access to, like, really
good information.
But when we know that something is intentionally sort of in the world of, like, fake news,
like, we need to make sure that we are actually providing, like, reality for people.
Right.
One last question for you.
You continue to evolve as a company.
You've, from, from the beginnings and the spit tube test and telling us about, you know,
various traits we have to now drug research.
Where do you see 23andMe in the next five, 10 years?
What, what's next?
I think, I, I love my company.
I love it so much.
I think that, like, I think about, again, for us, like one of the, you talked about
prevention.
And I really think, like, one of the most interesting things we can do is help people
live healthier and really understand prevention.
Like, if I go to my doctor, we're all, we're going to hear the exact same thing.
Like, exercise more, you know, lose weight, don't smoke.
And I think there's a huge opportunity of personalization.
Like, whether or not, like, we're both in our 40s.
Like, who should get a mammogram?
Should I get a mammogram?
Should you get a mammogram?
It's not the same for everyone.
Like, not all 40-year-olds are the same.
Not everyone has the same risk factor.
So, I think the next decade, for me, is about really crafting a world where we're truly
looking at all the information about you and how can we actually help you live a more personalized
life related to your health.
So, I think it's, again, that's why I said, like, I love the prevention space.
There's such a, there's so much potential.
And, again, no one, the issue, you know, no one really makes money on preventing diabetes.
But I think it's, without a doubt, that is what our customers want.
So, we will provide it.
All right.
Thank you so much.
Thank you.
